000163808 001__ 163808
000163808 005__ 20251107115328.0
000163808 0247_ $$2doi$$a10.1111/jdv.20705
000163808 0248_ $$2sideral$$a145817
000163808 037__ $$aART-2025-145817
000163808 041__ $$aeng
000163808 100__ $$aLluch-Galcerá, Juan José
000163808 245__ $$aCardiovascular safety of systemic psoriasis treatments: A prospective cohort study in the BIOBADADERM registry
000163808 260__ $$c2025
000163808 5203_ $$aBackground: Psoriasis is a chronic inflammatory disease with multiple comorbidities, including an increased risk of major adverse cardiovascular events (MACE). There is limited and contradictory evidence comparing the impact of systemic treatments for psoriasis on MACE.
Objectives: To evaluate the incidence of MACE associated with each systemic treatment used for patients with psoriasis and compare these rates to those observed with methotrexate (MTX).
Methods: We conducted a prospective cohort study using data from the BIOBADADERM registry. Propensity score matching was used to adjust for baseline differences between treatment groups. We calculated the incidence rate (IR) of MACE for each systemic treatment class, including biologics (anti-TNF, IL-12/23, IL-17 and IL-23 inhibitors), conventional systemic therapies (MTX, cyclosporine, dimethyl fumarate and acitretin) and apremilast (APR). The IR for each group was compared to those observed in patients treated with MTX using Poisson regression models adjusted for potential confounders, with 95% confidence intervals (95% CI). The primary outcome was the adjusted incidence rate ratios (IRR) for MACE between patients receiving MTX and those receiving another systemic treatment.
Results: We analysed data from 5622 patients, 11,368 treatment cycles and 21,762 person-years (PYs). APR (IRR = 0.17; 95% CI, 0.04–0.70) and IL-17 (IRR = 0.43; 95% CI, 0.20–0.91) were associated with a significant reduction in the risk of MACE compared to MTX. Cyclosporine was associated with an increased risk of MACE (IRR = 3.59; 95% CI, 1.17–10.99) compared to MTX. The remaining systemic psoriasis treatments were not significantly associated with an increased or decreased risk of MACE.
Conclusions: This real-world evidence study indicates a potential association between APR and IL-17 with a lower incidence of MACE, while CYC showed a higher incidence compared to MTX. These findings underscore the importance of considering cardiovascular outcomes when selecting systemic therapies for patients with psoriasis.
000163808 540__ $$9info:eu-repo/semantics/closedAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000163808 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000163808 700__ $$aCarrascosa, José Manuel
000163808 700__ $$aGonzález-Quesada, Alicia
000163808 700__ $$aSahuquillo-Torralba, Antonio
000163808 700__ $$aRivera-Díaz, Raquel
000163808 700__ $$aDaudén, Esteban
000163808 700__ $$aBelinchón, Isabel
000163808 700__ $$aGómez-García, Francisco José
000163808 700__ $$aHerrera-Acosta, Enrique
000163808 700__ $$aRuiz-Genao, Diana P.
000163808 700__ $$aLopez-Estebaranz, José Luís
000163808 700__ $$aBaniandrés-Rodríguez, Ofelia
000163808 700__ $$aFerrán, Marta
000163808 700__ $$ade la Cueva, Pablo
000163808 700__ $$aRodríguez, Lourdes
000163808 700__ $$aMateu, Almudena
000163808 700__ $$aRiera-Monroig, Josep
000163808 700__ $$aRuiz-Carrascosa, José Carlos
000163808 700__ $$0(orcid)0000-0001-8789-6783$$aAra-Martín, Mariano$$uUniversidad de Zaragoza
000163808 700__ $$aAbalde-Pintos, María Teresa
000163808 700__ $$aRoncero-Riesco, Mónica
000163808 700__ $$aPujol-Marco, Conrad
000163808 700__ $$aGarcía-Donoso, Carmen
000163808 700__ $$aLlamas-Velasco, Mar
000163808 700__ $$aDel Alcázar, Elena
000163808 700__ $$aSuárez-Pérez, Jorge Alonso
000163808 700__ $$aRodríguez-Sánchez, Belén
000163808 700__ $$aDíez-Madueño, Kevin
000163808 700__ $$aRuiz-Villaverde, Ricardo
000163808 700__ $$0(orcid)0000-0002-5317-7091$$aLezcano-Biosca, Victoria$$uUniversidad de Zaragoza
000163808 700__ $$aGonzález-Sixto, Beatriz
000163808 700__ $$aDescalzo, Miguel Ángel
000163808 700__ $$aGarcía-Doval, Ignacio
000163808 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000163808 773__ $$g39, 9 (2025), 1631-1642$$pJEADV, J. Eur. Acad. Dermatol. Venereol.$$tJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY$$x0926-9959
000163808 8564_ $$s353200$$uhttps://zaguan.unizar.es/record/163808/files/texto_completo.pdf$$yVersión publicada
000163808 8564_ $$s2449028$$uhttps://zaguan.unizar.es/record/163808/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000163808 909CO $$ooai:zaguan.unizar.es:163808$$particulos$$pdriver
000163808 951__ $$a2025-11-07-10:25:06
000163808 980__ $$aARTICLE